# Codebook — trial results in press releases (Paper No. 3)

Version 2 (after pilot coding round 1: α below .667 on the verdict, headline
and spin questions; categories that coders split are merged or made binary).

One coding = one (release, trial) pair. The coder sees the release text and the
trial's registry record as it stood on the release date (registered primary and
secondary outcomes, phase, allocation, sponsor class, status). The coder never
sees the publisher's name or website. Every evidence field quotes the release
verbatim (≤ 40 words); "" when the answer is "no" or "n/a".

**Code each trial on its own.** A release often names several trials. Answers
and evidence for a trial must concern THAT trial — never a sister trial, an
earlier phase, or the drug's results in general.

**The registered primary outcome** is the outcome (or outcomes) listed under
REGISTERED PRIMARY OUTCOMES for this trial. The release may use other words for
it (an abbreviation, a responder version of the same measure, the same measure
at the registered time point); it is the same outcome if the measure and the
time point match. A different measure, a different time point, a subgroup or a
post-hoc version is NOT the registered primary outcome.

## R1. Registered primary outcome type (from the registry record only)
`efficacy` if at least one registered primary outcome measures benefit
(response, survival, symptoms, a disease or biomarker measure used as the
efficacy measure); `safety/PK/dose` if every registered primary outcome is
adverse events, tolerability, laboratory or vital-sign changes,
pharmacokinetics, immunogenicity, dose-limiting toxicity or dose finding.

## Q0. Who issued the release? (once per release)
- `trial side` — the lead sponsor, a collaborator or licensing partner, or an
  institution of the trial's investigators, speaking in its own name (first
  person, its own quotes, its own contacts).
- `third party` — anyone else: a news-style rewrite of another
  organization's announcement, a law firm's investor alert, an analyst or
  market-research note, a conference organizer's release about many trials.
If `third party`, stop.

## Q1. Does the release report results of THIS trial?
- `results` — any efficacy or safety finding from this trial, including a
  regulatory approval release that states the trial's findings, and a
  qualitative statement such as "well tolerated" or "showed activity".
- `no` — the trial is only mentioned (start, enrolment, design, expected
  timing, a pipeline list, an approval or filing that cites it without any
  finding, a publication announced without any finding).
If `no`, stop.

## Q2. What kind of results announcement?
`topline` (first announcement of the main result) · `interim` · `final/full`
· `conference` · `publication` · `regulatory` (approval or filing) · `other`.

## Q3. Does the release name the trial's registered primary outcome?
`yes` — it names the measure (for a trial with several registered primary
outcomes: at least one of them). `no` — it does not ("efficacy", "safety",
"the primary endpoint" with no measure named do not count).

## Q4. What does the release say about the result of the registered primary outcome?
Work down the list; take the first that applies.
1. `not met` — says the outcome was not met, missed, did not reach
   statistical significance, or gives a p-value at or above the stated
   threshold (0.05 if none is stated).
2. `mixed` — several registered primary outcomes, at least one met and at
   least one not met.
3. `met` — says it was met, achieved, reached statistical significance, or
   gives a p-value below the threshold — for the registered primary outcome.
   "The study met its primary endpoint" counts as `met` even if the measure is
   not named, PROVIDED the release does not name a different outcome as that
   primary endpoint (then see Q5 and answer `no verdict`).
4. `number, no verdict` — gives a result for the registered primary outcome
   (an effect, a rate, a difference, a count) without saying whether it was met.
5. `no verdict` — anything else: the outcome is not mentioned, or mentioned
   without a result, or only described with words such as "encouraging",
   "clinically meaningful", "well tolerated", "consistent with".

## Q5. Does the release call some OTHER outcome this trial's primary?
`yes` — the release names, as this trial's primary (or main, principal)
outcome or endpoint, a measure or time point that is NOT a registered primary
outcome. Give the release's words. `no` — otherwise.

## Q6. Does the HEADLINE state a result of the registered primary outcome?
`yes` — the headline gives this outcome's verdict ("met its primary
endpoint", "missed primary endpoint") or names the outcome with a result.
`no` — otherwise (a generic "positive results", a secondary outcome, a
subgroup, safety, a milestone, an approval).

## Q7. Does the HEADLINE present the results as favourable?
`yes` — positive, met, superior, significant, improved, durable, promising,
encouraging, or an approval. `no` — neutral or unfavourable.

## Q8. Spin (only when R1 = `efficacy` and Q4 is `not met`, `mixed`,
`number, no verdict` or `no verdict`). Mark each that applies:
- `other favourable results` — the release highlights favourable results
  OTHER than the registered primary outcome: secondary outcomes, subgroups,
  post-hoc or responder analyses, change from baseline within one arm, an
  open-label extension;
- `trend as benefit` — a difference that is not statistically significant is
  presented as benefit ("trend", "numerically", "nominal", "clinically
  meaningful" without significance);
- `beneficial conclusion` — the release concludes the treatment works or is
  advancing to the next phase or to regulators, on the strength of the above;
- `none`.

## Q9. If Q4 = `met`: does the release give at least one number for the
registered primary outcome (effect, rate, difference, p-value or interval)?
`yes` · `no`.

## Q10. Coder's confidence: `high` · `medium` · `low`.
